Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

Hana Biosciences’ clinical trial agreement with the National Cancer Institute

Hana Biosciences (OTCBB:HNAB) announced a Clinical Trial Agreement with the Center for Cancer Research (CCR) at the National Cancer Institute for the co-development of Marqibo(R) (vincristine sulfate liposomes injection) in refractory pediatric cancer. The five-year agreement will initially focus on a Phase 1 trial to evaluate the safety, preliminary efficacy, pharmacokinetic profile, and weekly dose of Marqibo in children and adolescents with refractory cancer. Following the Phase I trial, the Company and CCR plan a Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Intarcia presents positive results of Type 2 Diabetes study

Intarcia Therapeutics, Inc. presented final results from its Phase 1b clinical study of ITCA 650 (DUROS® continuous delivery of exenatide) for the treatment of type 2 diabetes, which demonstrate substantial reductions in fasting plasma glucose (FPG) within 24 hours of the start of treatment and a sustained glucose lowering effect throughout the 28 day treatment period.  Other important results from the study were significant reductions in postprandial glucose (PPG), HbA1c and body weight.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

MDRNA patent allowance for siRNA

MDRNA, Inc. (NASDAQ: MRNA) announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application U.S. 11/624,630 covering an siRNA directed against a junctional adhesion molecule-1 (JAM-1) gene. The siRNA of the allowed claim has a broad array of potential applications, most notably as a therapeutic for the treatment of certain cancers, thrombosis, atherosclerosis, strokes, and hypertension; and enhances the delivery of drugs across the skin and the Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. complete merger

Raptor Pharmaceuticals Corp. (“Raptor”) (OTC Bulletin Board: RPTP) and TorreyPines Therapeutics, Inc. (“TorreyPines”) (Nasdaq: TPTX) announced the completion of their merger. The combined company is named “Raptor Pharmaceutical Corp.” and will commence trading today on the NASDAQ Capital Market under the ticker symbol “RPTP.” Pursuant to NASDAQ’s regulations, for the first 20 trading days the ticker symbol will be “RPTPd”. The combined company will be headquartered in Novato, California and managed by Raptor’s existing management Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

RegeneRx’s TB4 shows functional recovery in MS animal model

RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) announces significant improvement in neurological functional recovery after TB4 treatment of EAE (experimental autoimmune encephalomyelitis – an animal model for multiple sclerosis), according to Henry Ford Health System researchers. In addition, researchers reported a significant reduction of inflammation and induction of oligodendrogenesis (maturation of central nervous system cells associated with the formation of the nerve sheath). The study entitled, “Neurological Functional Recovery after Thymosin Beta 4 Treatment in Mice with Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,